161 related articles for article (PubMed ID: 36056084)
1. Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.
Allert C; Waclawiczek A; Zimmermann SMN; Göllner S; Heid D; Janssen M; Renders S; Rohde C; Bauer M; Bruckmann M; Zinz R; Pauli C; Besenbeck B; Wickenhauser C; Trumpp A; Krijgsveld J; Müller-Tidow C; Blank MF
Leukemia; 2022 Oct; 36(10):2418-2429. PubMed ID: 36056084
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
3. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
4. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
Waldeck S; Rassner M; Keye P; Follo M; Herchenbach D; Endres C; Charlet A; Andrieux G; Salzer U; Boerries M; Duyster J; von Bubnoff N
Mol Oncol; 2020 Apr; 14(4):779-794. PubMed ID: 31955503
[TBL] [Abstract][Full Text] [Related]
5. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
6. Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition.
Qiu S; Kumar H; Yan C; Li H; Paterson AJ; Anderson NR; He J; Yang J; Xie M; Crossman DK; Lu R; Welner RS; Bhatia R
Leukemia; 2022 Nov; 36(11):2621-2633. PubMed ID: 36220999
[TBL] [Abstract][Full Text] [Related]
7. 4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition.
Zhao XY; Zhang RR; Ye Q; Qiu F; Xu HY; Wei FG; Zhang H
Curr Med Sci; 2020 Oct; 40(5):810-816. PubMed ID: 33123895
[TBL] [Abstract][Full Text] [Related]
8. FLT3 Inhibition in Acute Myeloid Leukemia.
Smith CC
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S5-S6. PubMed ID: 32862867
[TBL] [Abstract][Full Text] [Related]
9. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
[TBL] [Abstract][Full Text] [Related]
10. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
[TBL] [Abstract][Full Text] [Related]
11. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
12. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Perl AE; Hosono N; Montesinos P; Podoltsev N; Martinelli G; Panoskaltsis N; Recher C; Smith CC; Levis MJ; Strickland S; Röllig C; Groß-Langenhoff M; Chou WC; Lee JH; Yokoyama H; Hasabou N; Lu Q; Tiu RV; Altman JK
Blood Cancer J; 2022 May; 12(5):84. PubMed ID: 35637252
[TBL] [Abstract][Full Text] [Related]
14. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
15. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
16. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.
Pfeiffer A; Franciosa G; Locard-Paulet M; Piga I; Reckzeh K; Vemulapalli V; Blacklow SC; Theilgaard-Mönch K; Jensen LJ; Olsen JV
Cancer Res; 2022 Jun; 82(11):2141-2155. PubMed ID: 35311954
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.
Morales ML; Arenas A; Ortiz-Ruiz A; Leivas A; Rapado I; Rodríguez-García A; Castro N; Zagorac I; Quintela-Fandino M; Gómez-López G; Gallardo M; Ayala R; Linares M; Martínez-López J
Sci Rep; 2019 Dec; 9(1):18630. PubMed ID: 31819100
[TBL] [Abstract][Full Text] [Related]
19. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
20. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
